Capricor Q3 2022 net loss $6.4M, cash $46.6M; HOPE-3 enrollment on track

CAPRICOR THERAPEUTICS, INC.

2022-Q3 EPS reported -$0.87 revenue$1,591,566

Revenue $1.6M from Nippon Shinyaku upfront recognition; net loss $0.26/shr vs $0.17/shr a year ago.
Cash and securities $46.6M as of Sept 30, 2022, up from $34.9M at year-end 2021.
Raised ~$1.9M through ATM at avg $5.72/shr; cash runway expected into Q2 2024.
HOPE-3 Phase 3 for CAP-1002 in DMD enrollment progressing; interim analysis expected mid-2023.
Positive one-year HOPE-2 open label extension data presented at WMS 2022; new StealthX exosome vaccine data shown.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CAPRICOR THERAPEUTICS, INC. reported third quarter ended September 30, 2022 results: revenue approximately $1.6 million, net income approximately $6.4 million, EPS $0.26 per share.

Period: third quarter ended September 30, 2022
Revenue: approximately $1.6 million
Net income: approximately $6.4 million
EPS: $0.26 per share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, the Company reported revenue of approximately $1.6 million compared with zero for the three months ended September 30, 2021. Operating expenses: Total operating expenses for the three months ended September 30, 2022, were approximately $8.1 million compared with approximately $4.3 million for the three months ended September 30, 2021. The Company reported a net loss of approximately $6.4 million, or $0.26 per share, for the third quarter of 2022, compared to a net loss of approximately $3.9 million, or $0.17 per share, for the third quarter of 2021.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-22-017398

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.